Details for New Drug Application (NDA): 020500
✉ Email this page to a colleague
The generic ingredient in MEPRON is atovaquone. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the atovaquone profile page.
Summary for 020500
Tradename: | MEPRON |
Applicant: | Glaxosmithkline Llc |
Ingredient: | atovaquone |
Patents: | 0 |
Suppliers and Packaging for NDA: 020500
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
MEPRON | atovaquone | SUSPENSION;ORAL | 020500 | NDA | GlaxoSmithKline LLC | 0173-0547 | 0173-0547-00 | 42 POUCH in 1 DOSE PACK (0173-0547-00) / 5 mL in 1 POUCH |
MEPRON | atovaquone | SUSPENSION;ORAL | 020500 | NDA | GlaxoSmithKline LLC | 0173-0665 | 0173-0665-18 | 210 mL in 1 BOTTLE (0173-0665-18) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 750MG/5ML | ||||
Approval Date: | Feb 8, 1995 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020500
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | 4,981,874*PED | ⤷ Subscribe |
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | 6,649,659*PED | ⤷ Subscribe |
Glaxosmithkline Llc | MEPRON | atovaquone | SUSPENSION;ORAL | 020500-001 | Feb 8, 1995 | 5,053,432*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription